Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.
J Med Case Rep · 2025
Last updated 2026-05-28A 17-year-old with juvenile Huntington disease and severe obesity (BMI of 44) was treated with semaglutide, a GLP-1 drug, starting at 0.25 mg weekly and increasing to 1 mg. After 3 months, his BMI dropped by 7% to 40, but he still faced obesity-related health issues. At 18, he underwent laparoscopic sleeve gastrectomy, and six months later, his BMI fell to 33, liver enzymes improved, sleep apnea resolved, and he reported better physical activity and quality of life.
AI summary of the abstract below.
| Journal | J Med Case Rep, 2025 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
BACKGROUND: Managing severe obesity in youth with chronic, progressive conditions, such as juvenile Huntington disease, presents unique challenges. Juvenile Huntington disease, is characterized by rapid neurodegeneration, with most patients experiencing a significant decline in motor and cognitive functions within 10-20 years of symptom onset, leading to reduced life expectancy. Obesity further complicates these conditions, reducing quality of life and exacerbating physical, cognitive, and metabolic dysfunctions. A multidisciplinary approach is essential to address these complex issues.
CASE PRESENTATION: A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m (190% of the 95th percentile) presented for obesity management. He experienced extreme food cravings and difficulty with portion control. After thorough discussions with the patient and his family, and with ethics consultation, a treatment plan was developed that included pharmacological and surgical interventions. Semaglutide was initiated at 0.25 mg weekly, titrating up to 1 mg. After 3 months, his body mass index reduced by 7% (40 kg/m). Despite this, he continued to experience obesity-related complications, including elevated liver enzymes and obstructive sleep apnea, and underwent laparoscopic sleeve gastrectomy at 18 years old. Six-months postoperatively, his body mass index decreased to 33 kg/m, liver enzyme levels improved, and his sleep apnea resolved. Additionally, he reported improved physical activity and enhanced quality of life.
CONCLUSION: This case illustrates the ethical considerations and challenges of managing severe obesity in juvenile Huntington disease. The decision to proceed with bariatric surgery prioritized improving quality of life, given the patient's limited life expectancy. The use of a multimodal treatment approach, including semaglutide and laparoscopic sleeve gastrectomy, significantly improved both physical health and psychosocial well-being. This case highlights the importance of shared decision-making in managing complex obesity cases in pediatric populations with neurodegenerative diseases.
Verbatim abstract via PubMed 41121434 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.